Akums Drugs and Pharmaceuticals Limited · NSE: AKUMS · BSE: 544222
Akums Drugs and Pharmaceuticals
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 08 Aug 2026.
Q1 FY27 · Consolidated
Revenue
1,166.63₹ Cr
+13.9% vs year ago
Net profit
100.98₹ Cr
+56.1% vs year ago
EPS, basic
6.53₹
+57.3% vs year ago
Net margin
8.7%
+2.3 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 1,166.63 | +13.9% | 100.98 | +56.1% | 6.53 | 08 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 1,157.87 | +9.7% | 81.34 | −45.6% | 5.53 | 25 Jul 2026 |
| Q3 FY26Oct–Dec 2025 | 1,159.59 | +14.8% | 67.67 | +2.1% | 4.33 | 13 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 1,017.53 | −1.5% | 42.70 | −35.9% | 2.66 | 13 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 1,024.03 | +0.5% | 64.69 | +5.7% | 4.15 | 08 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 1,055.55 | — | 149.61 | — | 9.64 | 26 May 2025 |
| Q3 FY25Oct–Dec 2024 | 1,010.41 | — | 66.31 | — | 4.26 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,033.09 | — | 66.65 | — | 4.37 | 09 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 1,019.11 | — | 61.21 | — | 4.21 | 30 Aug 2024 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 392.27 | +18.0% | 44.84 | −0.1% | 2.93 | 08 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 338.37 | +2.9% | 15.20 | −44.9% | 0.99 | 25 Jul 2026 |
| Q3 FY26Oct–Dec 2025 | 368.61 | +9.2% | 28.11 | −31.7% | 1.84 | 13 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 309.31 | −5.8% | 23.46 | −53.4% | 1.53 | 13 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 332.44 | +4.8% | 44.87 | +7.1% | 2.93 | 08 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 328.75 | — | 27.59 | — | 1.80 | 26 May 2025 |
| Q3 FY25Oct–Dec 2024 | 337.41 | — | 41.17 | — | 2.69 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 328.35 | — | 50.37 | — | 3.38 | 09 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 317.27 | — | 41.88 | — | 2.93 | 30 Aug 2024 |
18 filings on record for this company.